| Name | Support | Language | Availability | Edition date | Price | ||
|---|---|---|---|---|---|---|---|
|
Papier |
English |
Available |
9/4/2023 |
€46.00 |
|
||
Details
Radionuclide therapy using bone targeting radiopharmaceuticals is an effective palliative care option to reduce pain associated with advanced disease with bone metastases. Over the last 20 years, suitable therapeutic radionuclides are more widely available, meaning that the benefits of pain palliation therapy could reach more patients. This publication provides a broad overview on the current status of radiopharmaceuticals for bone pain palliation. It covers production of radionuclides, identification of bone seeking carrier molecules, preparation of stable complexes, in vitro and in vivo evaluations and dosimetry studies which are part of the development of these radiopharmaceuticals for clinical use. Details on production and quality control of the currently available products, provided here will be of use to scientists involved in the development of these radiopharmaceuticals.
Additional Info
| Author | International Atomic Energy Agency (IAEA) |
|---|---|
| Published by | IAEA |
| Cover | Paperback |
| Document type | Book |
| Theme | Nuclear medicine (including radiopharmaceuticals) |
| Edition | 2020 |
| Number of pages | 141 |
| Weight(kg.) | 0.2600 |
| Keyword | STI/PUB/2042,Nuclear medicine (including radiopharmaceuticals) |
